5 Stocks To Keep an Eye On in 2026, According to Experts

Core Viewpoint - The Dow Jones Industrial Average reached an all-time high at the beginning of the year, but there are still significant growth opportunities in various sectors, particularly healthcare, finance, and retail, especially if the U.S. Federal Reserve continues to lower interest rates [1] Healthcare Sector - Novo Nordisk ADR (NVO): The company is recognized for its diabetes drugs and GLP-1 weight loss injections. The stock experienced a 150% increase in 2023/24 but faced a decline in 2025 due to competition and pricing issues. Currently, it has a forward P/E of around 16 and a dividend yield of 3%. A new oral pill version of Wegovy has been approved, and there is a potential upside of 50% in 2026 if shares can be acquired for under $60 [2][3] - Eli Lilly (LLY): This company is a competitor to Novo Nordisk, known for its tirzepatide injections and other medications. Eli Lilly is involved in AI for drug development, with a significant investment from Nvidia. The stock has a "Strong Buy" rating with a high price target of $1,500, closing at $1,078.52 on January 21 [4][5] Retail Sector - TJX Companies Inc. (TJX): The company operates discount retailers such as T.J. Maxx and Marshalls, and is positioned favorably compared to many competitors in the retail space, indicating potential for growth [6]